Q1 Earnings Estimate for Teleflex Issued By Citizens Jmp

Teleflex Incorporated (NYSE:TFX) – Equities researchers at Citizens Jmp issued their Q1 2025 EPS estimates for shares of Teleflex in a research note issued on Wednesday, April 2nd. Citizens Jmp analyst D. Turkaly forecasts that the medical technology company will post earnings per share of $2.77 for the quarter. Citizens Jmp has a “Market Perform” rating on the stock. The consensus estimate for Teleflex’s current full-year earnings is $13.98 per share. Citizens Jmp also issued estimates for Teleflex’s Q2 2025 earnings at $3.45 EPS, Q3 2025 earnings at $3.70 EPS, Q4 2025 earnings at $4.18 EPS, FY2025 earnings at $14.10 EPS, Q1 2026 earnings at $3.47 EPS, Q2 2026 earnings at $3.80 EPS, Q3 2026 earnings at $3.88 EPS, Q4 2026 earnings at $4.10 EPS and FY2026 earnings at $15.25 EPS.

A number of other equities analysts have also issued reports on TFX. Needham & Company LLC reaffirmed a “hold” rating on shares of Teleflex in a research report on Wednesday, March 12th. Wells Fargo & Company dropped their price objective on shares of Teleflex from $214.00 to $146.00 and set an “equal weight” rating on the stock in a report on Friday, February 28th. Piper Sandler reiterated a “neutral” rating and issued a $140.00 target price (down previously from $255.00) on shares of Teleflex in a research note on Friday, February 28th. Royal Bank of Canada lowered Teleflex from an “outperform” rating to a “sector perform” rating and lowered their price target for the company from $220.00 to $155.00 in a research note on Friday, February 28th. Finally, Bank of America cut Teleflex from a “neutral” rating to an “underperform” rating and cut their price target for the company from $235.00 to $140.00 in a report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $182.63.

Teleflex Stock Down 0.7 %

Shares of TFX stock opened at $130.95 on Monday. Teleflex has a 12 month low of $127.18 and a 12 month high of $249.91. The company has a quick ratio of 1.39, a current ratio of 2.42 and a debt-to-equity ratio of 0.37. The firm has a market cap of $6.07 billion, a PE ratio of 26.03, a price-to-earnings-growth ratio of 1.73 and a beta of 1.19. The stock has a 50 day moving average of $153.81 and a 200-day moving average of $185.45.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, February 27th. The medical technology company reported $3.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.86 by $0.03. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The company had revenue of $795.40 million for the quarter, compared to the consensus estimate of $813.24 million.

Teleflex Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, March 17th. Investors of record on Friday, March 7th were paid a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 1.04%. The ex-dividend date of this dividend was Friday, March 7th. Teleflex’s dividend payout ratio is 95.77%.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. grew its holdings in shares of Teleflex by 4.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,173,121 shares of the medical technology company’s stock worth $1,098,693,000 after purchasing an additional 261,279 shares during the last quarter. State Street Corp grew its stake in Teleflex by 1.0% during the third quarter. State Street Corp now owns 2,057,080 shares of the medical technology company’s stock worth $508,757,000 after buying an additional 21,291 shares during the last quarter. Geode Capital Management LLC grew its stake in Teleflex by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 1,138,867 shares of the medical technology company’s stock worth $202,161,000 after buying an additional 8,307 shares during the last quarter. Cooke & Bieler LP increased its holdings in shares of Teleflex by 22.1% during the fourth quarter. Cooke & Bieler LP now owns 1,078,557 shares of the medical technology company’s stock worth $191,962,000 after buying an additional 195,150 shares in the last quarter. Finally, Invesco Ltd. raised its stake in shares of Teleflex by 48.1% in the fourth quarter. Invesco Ltd. now owns 1,068,593 shares of the medical technology company’s stock valued at $190,188,000 after acquiring an additional 347,003 shares during the last quarter. 95.62% of the stock is currently owned by institutional investors and hedge funds.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.